Predictive biomarkers of response to immune checkpoint inhibitors in mismatch repair-deficient endometrial cancer.

Ther Adv Med Oncol · 2026 · PMC12988271 · PMID 41835337

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Additionally, a larger study showed a trend toward reduced OS in patients with MLH1 -methylated ECs following ICI therapy. 33 However, these observations have not been confirmed in larger biomarker exploratory analyses conducted across three different clinical trials.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.